Nambling, Rowena .
HRN: 01-00-24 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/30/2025
CEFUROXIME 1.5GM (VIAL)
03/30/2025
04/05/2025
IV
1.5g
Q8
Epidermal Cyst
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes